跳到正文
原文
Nature 健康护理主题·· 10 小时前精选AI 评分85

医学状况复杂患者的牙周管理专家共识发布

Expert consensus on periodontal management for medically compromised patients

AI 导读

国际口腔科学杂志发表专家共识,系统梳理牙周炎与糖尿病、心血管疾病、骨质疏松、呼吸系统疾病、肝肾疾病、肿瘤及血液病等的双向关联机制,并提出分层治疗策略。共识建议按HbA1c水平、血压分级及凝血指标进行风险分层,明确妊娠期、化疗期及抗吸收药物使用期间的牙周干预时机,为全身合并症患者提供操作指引。

推荐理由

多专科专家联合制定,按HbA1c及血压等分层给出牙周治疗时机与方案调整建议,便于临床医生快速对照决策。

正文 · 原文
  • Review Article
  • Open access
  • Published: 20 November 2026

International Journal of Oral Science volume 18, Article number: 74 (2026) Cite this article

Abstract

Periodontitis is a highly prevalent oral disease that extends beyond local inflammation and tissue destruction to exert a profound influence on systemic health. With the growing burden of multimorbidity, where multiple systemic disorders frequently co-exist, periodontal management has become increasingly complex, yet clear and integrated guidance for this specific patient population remains limited. This manuscript synthesizes current evidence on the bidirectional relationship between periodontitis and systemic conditions, proposes recommendations for dynamic periodontal management, and updates relevant therapeutic strategies. This expert consensus is designed to ensure both the safety and efficacy of periodontal treatment, reduce the risk of complications, and ultimately promote oral and general well-being.

Introduction

Periodontitis is a worldwide health challenge with a high prevalence. Uncontrolled periodontitis results in the destruction of periodontal tissues and eventual tooth loss. Global Burden of Disease (GBD) data recently projected a significant rise in the impact of oral diseases. Worldwide, severe periodontitis is expected to rank the 30th (up from the 31st in 2021) among Level-4 leading diseases/conditions affecting numbers of Years Lived with Disability (YLDs), while edentulism is set for a more dramatic climb from 24th to 15th place by 2050.1 China is among the top three countries with a serious burden of periodontal diseases and is projected to have approximately 130.23 million edentulous individuals, which represents 19.67% of the global burden.2 Meanwhile, China faces a substantial burden of systemic diseases.3,4

Periodontitis extends beyond local inflammation to constitute an ongoing source of systemic inflammatory burden. As recently reviewed,5 the systemic impact of periodontal inflammation is mediated by a broad array of interconnected pathways, including microbial translocation with their virulence factors and metabolites, mobilization of primed oral immune cells and locally derived autoantibodies, oral–gut microbial dysbiosis, trained immunity that sustains a chronic hyperinflammatory state, cellular senescence, diverse epigenetic alterations, and nutritional/metabolic derangements arising from masticatory dysfunction in severe cases. The convergence of these mechanisms reinforces the notion that periodontal health is integral to systemic well-being.6,7,8,9,10 Notably, periodontitis was found to significantly increase the risk of all-cause and cause-specific mortality.11 Thus, personalized periodontal management with a full evaluation of systemic factors is essential to reduce treatment risk, improve therapeutic effects, and eventually facilitate oral and systemic health.12 With the continuous studies of the interactions between systemic factors and periodontitis and the development of pharmacotherapy for these systemic diseases, the need for comprehensive principles of periodontal management becomes increasingly evident.

In the following sections, the development process and specific methodologies of this consensus are first described below, followed by an outline of the general principles of periodontal management (Fig. 1). For each condition, we provide: (i) a brief background on its latest epidemiology and underlying molecular mechanisms; (ii) clinical guidance recommendations for dynamic periodontal management, including implant therapy when indicated; (iii) clinical precautions; and (iv) current developments on bidirectional therapeutic benefits.

Fig. 1

Overall clinical flowchart for dynamic periodontal management. CVDs Cardiovascular diseases, CKD Chronic kidney disease, OHI oral hygiene instruction

Methods

The consensus was initiated by experts from the Chinese Society Periodontology of the Chinese Stomatological Association in collaboration with multidisciplinary experts from cardiovascular medicine, endocrinology, respiratory medicine, and obstetrics and gynecology.

The systemic conditions addressed in this consensus, including diabetes, cardiovascular diseases, osteoporosis, respiratory diseases, liver/kidney diseases, cancer, hematological disorders, and hormonal imbalances, were selected considering their association with periodontitis and/or their implications for periodontal therapy, particularly in terms of treatment safety and risk management. Communicable diseases are not the primary focus of this consensus; however, infectious respiratory diseases and active viral hepatitis are briefly addressed in the respective sections due to their specific implications for cross-infection control. Other communicable diseases are not covered. A systematic literature search was conducted for high-quality clinical studies, meta-analyses and systematic reviews, clinical guidelines, expert consensus and authoritative textbooks pertaining to periodontitis and the above‑mentioned systemic conditions.

To grade the clinical guidance recommendation, we adopted the European Society of Cardiology (ESC) 2024 evidence level system for therapy and prevention with minor modifications: Grade A indicates conclusive evidence from ≥2 adequately powered randomized controlled trials (RCTs); Grade B indicates suggestive/limited evidence from ≥1 RCT or ≥2 powered non-randomized studies, or derived from clinical guidelines, expert consensus or authoritative textbooks, consolidating its B1 and B2 sublevels into a single Grade B to improve applicability in clinical settings; Grade C indicates preliminary evidence based primarily on expert experience or clinical logic.13

Grades were assigned independently by two core experts based on study design and quality, with disagreements resolved through discussion. For recommendations drawn from previously published consensus statements, the original source evidence was traced and verified. Consensus was reached via a modified Delphi process over two rounds, with consensus defined as ≥ 80% of the panel giving a score of 7 or higher on a 9-point Likert scale.14 All recommendations in this manuscript achieved consensus after the review process (overall agreement rate > 95%). Grades are shown as [A]/[B]/[C] after each recommendation. A summary of all recommendations, with the rationale for each grading, is provided in Table S1.

General principles and comprehensive management framework

Raising the awareness of periodontal health

  • To raise public awareness of periodontal health, science popularizations about the importance of oral hygiene, the value of scheduled oral examinations, and the role of periodontal health in overall health should be strengthened.

  • It is recommended that physicians remind patients with systemic diseases of the bidirectional susceptibility of periodontitis and certain systemic diseases, regular oral examinations, and necessary periodontal therapy.

  • For some systemic diseases, symptoms can sometimes be first detected in the dental clinic. Thus, dentists should recommend that patients with certain oral symptoms undergo necessary systemic examinations and treatments.

Pretreatment assessment

  • To identify systemic conditions or detect potential disorders, detailed inquiries about systemic diseases, medication, and family history, combined with periodontal and associated laboratory examinations, are essential.

Risk stratification and treatment modification This consensus adopts the EFP S3-level four-step framework (Step 1: risk factor control and professional mechanical plaque removal (PMPR); Step 2: subgingival instrumentation; Step 3: periodontal surgery; Step 4: supportive periodontal care (SPC)) to guide the treatment modifications outlined in each disease-specific section. Wherever appropriate, we have indicated the relevant step alongside the corresponding recommendation.

  • For patients presenting with acute conditions, advice from the relevant physicians should be sought prior to periodontal intervention.

  • Individualized long-term therapeutic strategies should be developed based on the patient’s clinical status.

  • Multidisciplinary combined treatment is necessary to restore complete dentition and mastication function, especially for advanced stages of periodontitis, which will facilitate both periodontal and overall health.15

Supportive care

  • During the phase of SPC, oral hygiene instruction and the possibility of recurrence should be emphasized to patients at every visit.

  • During the first 12 months after positive periodontal therapy, patients with good periodontal conditions should have regular follow-up visits at the 3rd, 6th, and 12th month. After the first 12 months, the recall interval is not recommended to exceed 6 to 12 months. The follow-up visits can be adjusted based on individual conditions, such as oral hygiene status, periodontal examination results, and systemic conditions.16

  • Supportive therapy should be performed based on the results of periodontal examinations during follow-up visits.

Diabetes mellitus

Background

Diabetes mellitus (DM) is one of the non-communicable diseases with high prevalence and fatality rate. Covering 217 countries from 2005 to 2024, the GBD study estimated that 589 million adults were affected by diabetes in 2024. Looking ahead, the number of adults is projected to climb to approximately 853 million by 2050.17

Owing to risk factors such as high fasting plasma glucose levels, high body mass index (BMI), diet-related factors, and air pollution, China currently bears the largest share of the diabetes burden, constituting 25.1% of all cases worldwide. In China, over 90% of all diabetes cases are attributable to type 2 diabetes mellitus (T2DM). Meanwhile, the proportion of the Chinese population who are diagnosed with prediabetes is considerably high. More seriously, an estimated 60% of individuals with diabetes are unaware of their condition, which results in a large population with undiagnosed diabetes.18,19,20

Diabetes is one of the grading factors according to the 2018 new classification of periodontitis.21 According to recent meta-analyses, individuals with periodontitis have a 19% to 26% higher risk of developing T2DM, while those with diabetes experience significantly higher rates of tooth loss.22 The systemic effects of periodontitis are principally driven by microbial translocation and systemic inflammatory burden. Under hyperglycemic conditions, these responses are amplified. Emerging evidence suggests that epigenetic reprogramming triggers maladaptive myelopoiesis and trained innate immunity, subsequently polarizing mononuclear macrophages toward a pro-inflammatory phenotype and perturbing the host-microbiome equilibrium.23,24 Meanwhile, immunometabolic alterations, such as abnormal glycolysis, impair osteogenic differentiation and exacerbate alveolar bone loss.25

Clinical guidance recommendation

Pretreatment assessment

  • The glycemic level should be evaluated and controlled during periodontal management.26 [B]

  • The recommended glycemic target from the Chinese Diabetes Society for non-pregnant adults with T2DM is a glycated hemoglobin A1c (HbA1c) level below 7%.27 [B]

Risk stratification and treatment modification

The following modifications to periodontal management are stratified according to the patient’s HbA1c levels (Fig. 2).

  • For patients with ideal glycemic control (HbA1c < 6.5%): Treatment plans should be made the same as for people without diabetes.28 [B]

  • For patients with good glycemic control (HbA1c 6.5–7.5%): Regular treatment plans can be made, while Steps 1 and 2 non-surgical periodontal therapy (NSPT) should be given priority.28 [B]

  • When glycemic levels are not well controlled (HbA1c > 7.5%):Quadrant-based Steps 1 and 2 NSPT are recommended over full-mouth protocols to shorten each session and prevent the acute-phase response.29 [B] For possible Step 3 surgical treatments, HbA1c is recommended to be less than 8%.30 [B]

  • For patients with poorly glycemic control (HbA1c > 10%): Only emergency treatment to control acute periodontal infection should be made until glycemic levels are effectively controlled.30 [B]

Fig. 2

Decision-making chart for patients with diabetes by evaluating the HbA1c level.15,26,30 HbA1c glycated hemoglobin A1c

Clinical precautions

Based on available evidence, periodontal therapy is generally safe and effective in patients with diabetes.31 However, the challenges increase in response to the severity of diabetes. Beyond the procedural modifications above, clinicians should also attend to the following systemic and interdisciplinary precautions during periodontal management:

  • Bidirectional links—screening and interdisciplinary referral: Routine screening for diabetes and prediabetes should be considered in patients with periodontitis, especially those with risk factors such as high fasting plasma glucose, high BMI, and diet-related factors. Meanwhile, endocrinologists should refer patients with established diabetes and poor glycemic control for periodontal examination and treatment.31

  • Prevention of intraoperative hypoglycemia: Patients receiving insulin, sulfonylureas, or other glucose-lowering agents should consult their physicians before surgery, so that their medication regimen can be adjusted to prevent intraoperative hypoglycemia.15

  • Post-surgical complications: Clinicians should be aware that uncontrolled diabetes was found to increase post-periodontal surgical complications, such as swelling, bleeding, infection, delayed wound healing, and flap dehiscence.32

Therapeutic benefits

The bidirectional relationship between periodontitis and diabetes has received increasing attention in recent years.31 In patients with periodontitis and T2DM, combining PMPR with hyaluronic acid gel, probiotics, or antibiotics achieved greater clinical improvement and a larger reduction in HbA1c than PMPR alone.33,34,35 Notably, in terms of improving glycemic regulation among T2DM patients with moderate-to-severe periodontitis, a stepwise periodontal strategy encompassing NSPT, necessary periodontal surgery, and SPC has demonstrated marked advantages over routine supragingival scaling and polishing.36 Conversely, the presence of diabetes has been found to significantly compromise the efficacy of periodontal therapy.37

Because of the high-glucose inflammatory microenvironment, which induces an exacerbated inflammatory cascade, oxidative stress responses, and dysregulated collagen synthesis,25,38,39 no clinically effective treatment has yet been found that can achieve ideal periodontal bone regeneration.40 Multiple strategies such as novel materials (e.g., supramolecular photothermal materials and drug-loaded microspheres) and treatment methods (e.g., laser therapy) are being tested for tissue regeneration in diabetic individuals.40,41,42

Cardiovascular diseases

Background

Cardiovascular diseases (CVDs) refer to a series of pathological conditions including coronary heart disease, atherosclerosis, rheumatic heart disease, hypertension, and heart failure. As a leading cause of mortality, GBD 2023 estimated that the number of prevalent CVD cases was 626 million globally.43 In China, CVDs are experiencing an increasing prevalence under the dual challenges of an aging population and uncontrolled metabolic risk factors; the total number of people diagnosed with CVDs has already reached around 330 million.44 Generally, periodontitis has been associated with a 31% increase in the risk of developing CVDs according to the latest meta-analysis.45 Taking patients with hypertension as an example, the risk of CVD mortality in these people with periodontitis was significantly higher than in those without periodontitis.46 Similarly, patients with carotid atherosclerosis (CAS) have been shown to have a higher prevalence of severe periodontitis than those without CAS.47

The mechanistic interplay between periodontitis and CVDs is multifaceted. Periodontal pathogens can directly invade the vascular endothelium, compromising endothelial integrity and function.48,49 In parallel, the bone marrow-vascular axis contributes to local vascular inflammation and elevates CVD risk through the modulation of trained myeloid cells.50,51 More recently, research focus has shifted upstream to the oral-gut microbiota, where dysbiosis is proposed to trigger cardiovascular dysfunction via bacterial metabolites and virulence factors.52

Clinical guidance recommendation

Pretreatment assessment

  • Blood pressure should be measured. In China, under tolerable conditions, the clinical blood pressure is recommended to be controlled below 130/80 mmHg for most hypertensive patients.53 [B]

  • Due to the multitude of potential causes of bleeding, comprehensive assessment of multiple coagulation-related parameters is recommended.54 [B]

Risk stratification and treatment modification

Generally, periodontal therapy is considered safe regarding the risk of CVDs.55 In terms of Steps 1 and 2 NSPT, scheduling periodontal treatment in multiple shorter sessions may be considered for patients with CVDs, as intensive protocols (full-mouth within 24 h) have been shown to trigger transient elevation of inflammatory markers and endothelial dysfunction.56

Hypertension

Based on blood pressure levels, modifications to periodontal treatment protocols are stratified as follows.28,53

  • Pre-condition (130 – 139/80 – 89 mmHg): Treatment plans should be made the same as those for people with normal blood pressure. [B]

  • Stage Ⅰ (140 – 159/90 – 99 mmHg): Blood pressure measurement is necessary at each visit. Treatment plans should be made the same as for people without hypertension. [B]

  • Stage Ⅱ (160 – 179/100 – 109 mmHg): Steps 1 and 2 NSPT are more recommended in such circumstances. Step 3 periodontal surgery should only be performed after the patient’s blood pressure is adequately controlled.55 [B]

  • Stage Ⅲ (above 180/110 mmHg): Active cardiovascular treatment should be initiated first, while only emergency treatment can be provided for acute periodontal infections. [B]

Abnormal coagulation function

When patients with CVDs suffer from abnormal coagulation function or are receiving antiplatelet and anticoagulant therapy (such as aspirin, clopidogrel, rivaroxaban, and warfarin), periodontal and systemic treatment plan should be adjusted accordingly as follows (Fig. 3).

  • Periodontal treatment modification: Step 3 periodontal surgery is not recommended when platelet counts are below 80 × 109 per L. When platelet counts are below 60 × 109 per L, even Steps 1 and 2 NSPT are not recommended. The INR should be maintained below 3.5 for patients undergoing dentoalveolar surgical procedures.30,57 [B]

  • Antiplatelet/anticoagulant management: There is no current evidence supporting discontinuation of antiplatelet therapy in various therapeutic dosages for treatments with a low bleeding risk. Prior to treatments with low to moderate bleeding risk for patients with an INR of 3.5 or higher, anticoagulant agents (e.g., warfarin) are recommended to be discontinued after negotiation with responsible medical professionals.55 [B]

  • Critical thresholds: Platelet counts below 50 × 10⁹ per L or an INR of 3.5 or higher are considered critical thresholds, and qualified medical professionals should be consulted before periodontal therapy.58 [B]

Fig. 3

Decision-making chart for patients with abnormal coagulation parameters.26,30,57,58,209 *Low bleeding risk group includes NSPT, conventional periodontal surgeries (conservative, resective or regenerative), tooth extractions, and dental implant placement. The moderate bleeding risk group includes most procedures of autogenous bone augmentation, sinus floor elevation, and soft tissue surgeries (e.g., free gingival graft and connective tissue graft). CVDs: Cardiovascular diseases; INR: international normalized ratio; NSPT: non-surgical periodontal therapy

Other acute conditions

  • Acute myocardial infarction and heart valve replacement: Periodontal therapy and implant placement should be performed only after a 6-month waiting period and following evaluation by cardiovascular specialists.28,59 [B]

  • Unstable angina pectoris: Emergency treatment should take precedence over complex periodontal therapy.28 [B]

Clinical precautions

  • Antibiotic prophylaxis—interdisciplinary coordination: Considering the possibility of bacterial colonization via the bloodstream induced by periodontal examination and treatment, prophylactic use of antibiotics is recommended for patients with congenital heart disease, heart valve replacement, a past medical history of infectious endocarditis (IE), or valvular heart disease following heart transplantation.30,60 For adult patients with a high risk of IE, antibiotic prophylaxis is recommended based on the 2023 ESC Guidelines. A single dose of antibiotic prophylaxis should be administered 30–60 minutes before the procedure. In patients without penicillin allergy, amoxicillin is preferred; alternatives include ampicillin, cefazolin, or ceftriaxone. For patients with penicillin allergy, oral options include cephalexin, azithromycin, clarithromycin, or doxycycline. For pediatric patients, dosing should be adjusted based on weight, age, and allergy history.61

  • Perioperative hemostasis—local measures and medical consultation: Persistent bleeding at sites with deep periodontal pockets is common in patients with CVDs, particularly those receiving anticoagulant and/or antiplatelet therapy, or those with poorly controlled hypertension.62 It should be noted that local hemostatic procedures (e.g., local compression, absorbable gelatin sponges, and sutures) are effective for most perioperative bleeding.55 When gingival bleeding cannot be effectively controlled by local hemostatic treatment, timely consultation with physicians is recommended for other measures. Moreover, intensive periodontal treatment should not be applied until CVDs-related risk factors for gingival bleeding have been controlled.

  • Drug-induced gingival enlargement—periodontal management and medication review: Drug-induced gingival enlargement, caused by several medications including calcium channel blockers used for hypertension (e.g., nifedipine and amlodipine), is mainly associated with poor oral hygiene and gingival inflammation.63,64 Because the latter factors are modifiable, periodontal therapy is effective in managing this condition. When gingival inflammation has been primarily controlled by Steps 1 and 2 NSPT, remaining overgrown gingival tissue should be removed by gingivectomy (Step 3 surgery).65 Accumulating evidence suggests that medication modification is not necessary unless intensive periodontal therapy fails to control the gingival enlargement.66,67

Therapeutic benefits

Management of periodontitis has been shown to improve endothelial function, which will, to some extent, facilitate the control of CVDs. For instance, the level of soluble E-selectin, one of the important endothelial-activation markers, was reported to be significantly decreased at 6 months post NSPT.68 Periodontal therapy has been found to reduce the risk of CVDs by alleviating inflammation and facilitating glycemic control.69 More recently, blood pressure and C-reactive protein levels were found to be reduced by periodontal therapy.70 Novel materials such as a dual-functional hydrogel platform integrating antibacterial and anti-inflammatory properties to simultaneously control periodontitis and hypertension are being studied.71 However, high-quality evidence is currently lacking to assess the benefits of periodontal therapy on reducing the occurrence or recurrence of cardiovascular events.

Osteoporosis

Background

Osteoporosis is a metabolic skeletal disorder featuring reduced bone mineral density and microarchitectural deterioration. As the elderly population increases, osteoporosis is regarded as a major health problem. The global prevalence of osteoporosis in elders was estimated as 21.7%, while the highest prevalence was found in Asia (24.3%).72 In China, 90 million people were estimated to suffer from osteoporosis.73 A link between low bone mineral density and more severe periodontitis has been observed in postmenopausal women, but the evidence from both individual studies and meta-analyses remains limited.74,75

Osteoporosis and periodontitis are both regarded as osteoimmune-related diseases, wherein immune cells modulate the activities of osteoclasts and osteoblasts.76 This osteoimmune imbalance is further accentuated by trained osteoclastogenesis, cellular senescence with its associated secretory phenotype, and signals from the oral-gut-bone axis, a process that exacerbates bone loss while compromising regenerative capacity.77,78,79

Clinically, antiresorptive agents (e.g., bisphosphonate and denosumab) and anabolic agents (e.g., teriparatide and romosozumab) are used to treat osteoporosis.80 However, long-term anti-resorptive therapy carries a risk of medication-related osteonecrosis of the jaw (MRONJ). MRONJ is a complication attributed to excessive suppression of bone turnover, reduced vascular perfusion, and impaired mucosal immune defense. It warrants particular attention in periodontal management.81,82

Clinical guidance recommendation

There is no specific contraindication to periodontal management in patients with osteoporosis. However, given the osteoporosis-related microenvironment that affects osteogenic activity, periodontal regenerative surgery becomes more challenging and requires careful evaluation.83 Meanwhile, clinicians should be aware of some special populations, such as postmenopausal women, the elderly, smokers, and people with obesity, who are prone to experience osteoporosis.84,85,86 The susceptibility to osteoporosis and the difficulties in alveolar bone regeneration should be emphasized to these people.

Pretreatment assessment

The medication history should be evaluated before treatment.

  • Type of antiresorptive agents: A recent retrospective cohort study utilizing the TriNetX global collaborative network found that denosumab was associated with the highest risk of MRONJ, followed by zoledronic acid, whereas ibandronate had the lowest risk.82 [C]

  • Treatment duration: Longer duration of antiresorptive therapy has been identified as a risk factor for MRONJ in patients with osteoporosis. Nevertheless, evidence regarding the precise threshold duration associated with elevated risk is currently inconsistent.87 [B]

  • Route of administration: Intravenous injection is more likely to cause MRONJ than oral administration.87 [B]

Risk stratification and treatment modification

Periodontal and peri-implant inflammation were considered important risk factors for MRONJ.88,89,90,91 Principles for periodontal management on antiresorptive therapy are discussed below (Fig. 4).

Fig. 4

Decision-making chart for patients on antiresorptive therapy.80,81,87,95,151 MRONJ, medication-related osteonecrosis of the jaw

Before antiresorptive therapies

  • Given that long-term antiresorptive therapy increases the risk of MRONJ, which can be mitigated by good oral hygiene and periodontal health, periodontal treatment before initiating antiresorptive therapy is recommended to reduce MRONJ incidence.87 [B]

  • Antiresorptive therapy alone should not preclude implant placement in osteoporotic patients, as current evidence does not confirm a substantially increased MRONJ risk in this setting.92 [C]

During antiresorptive therapies

  • Generally, local therapies are considered safe during antiresorptive therapy in patients with nonmalignant diseases such as osteoporosis. Currently, drug holidays of antiresorptive agents for dentoalveolar surgeries remain controversial.87 [B]

  • It was recently found that periodontal management, especially during the first three years of antiresorptive therapy, is crucial for preventing peri-implantitis and thus reducing the risk of MRONJ-related implant failure.93 [C]

Clinical precautions

  • Long-term implant maintenance—patient education: To date, the role of antiresorptive therapies in implant failure among osteoporotic patients remains unclear.94 Nevertheless, patients with already-placed implants should be informed about the low risk of implant failure as well as the importance of long-term maintenance.87

  • MRONJ prevention—perioperative management and systemic risk modification: To reduce the risk of MRONJ induced by periodontal and implant therapy, perioperative antimicrobial prophylaxis, including systemic antibiotics and antimicrobial mouthwash before and after treatment, is recommended. At the same time, other risk factors for MRONJ should be modified, including diabetes control and smoking cessation.87

  • MRONJ treatment—surgical intervention and debridement: Although generally considered safe, periodontal therapy may carry a risk of MRONJ, as reported in a patient receiving denosumab who developed MRONJ after Steps 1 and 2 NSPT.95 For such circumstances, under the premise of systemic antibiotics and local antimicrobial treatment, related teeth should be extracted, and necrotic bone should be removed with complete debridement.95

  • Emerging locally bisphosphonate therapy—cautious evaluation: Intriguingly, the potential therapeutic role of locally administered bisphosphonates as small-molecule adjuncts in periodontal treatment is currently under investigation, and reported studies have demonstrated significant improvements in clinical parameters.96,97 However, considering the possible complications mentioned above, clinical application of such antiresorptive agents requires comprehensive evaluation.

Therapeutic benefits

Combined application of NSPT and metformin showed obvious improvement in systemic bone loss.84 Novel materials such as reactive oxygen species-responsive hydrogels have been investigated to function as anti-inflammatory and anti-oxidative agents in periodontitis-related osteoporosis.98,99 Treatment of osteoporosis was found to improve periodontal conditions, which is corroborated by the lower prevalence of severe periodontitis observed in treated patients compared to untreated ones.100

Respiratory diseases

Background

According to the GBD 2023 study, the global burden of chronic respiratory diseases continues to rise alongside population growth and aging, with an estimated 569.2 million prevalent cases and 4.2 million deaths worldwide in 2023.101 Chronic respiratory diseases rank as the third most common cause of mortality in China, with an estimated 1.33 million deaths each year.102

Growing data suggest the bidirectional relationships between periodontitis and respiratory diseases. To date, the risk of respiratory diseases has been found to be increased in patients with periodontitis, including community-acquired pneumonia (CAP),103 hospital-acquired pneumonia (HAP),104 chronic obstructive pulmonary disease (COPD),105,106 obstructive sleep apnea (OSA),107 lung abscess,108 and pulmonary fibrosis.109 COPD patients have a 35% higher prevalence of periodontitis than non-COPD controls, albeit based on low-quality evidence.110 The relationship between periodontitis and asthma remains controversial, although the application of adrenergic inhalers was found to increase the risk of periodontitis and its progression to advanced stages.111

Inflammation, poor oral hygiene, and the immunosuppressive effect of corticosteroids, which are used for certain types of respiratory diseases such as asthma, are considered respiratory-related stimulative factors of periodontitis.112 Patients with respiratory insufficiency often exhibit compensatory mouth breathing, leading to oral dryness and reduced self-cleaning capacity, which further exacerbates plaque accumulation and gingival inflammation.113 On the contrary, increased periodontal pathogens were not only found in subgingival plaque samples,114,115 but were also detected in lung tissues and associated tissue fluid in people with pulmonary diseases.108,116,117 It was recently reported that the translocated periodontal pathogens could activate alveolar epithelial cells and subsequently promote neutrophil chemotaxis, thereby exacerbating airway inflammation and lung function decline.118 Other possible mechanisms by which periodontal pathogens promote the progression of pulmonary diseases include dysregulating the composition and function of bacterial biofilms in the respiratory tract,119 weakening the biological function of pulmonary epithelial cells,120 and inducing increased mucous secretion in the respiratory system.121

Clinical guidance recommendation

Pretreatment assessment

For patients with respiratory diseases, close monitoring of the patient’s respiratory status is required during treatment. To rapidly identify high-risk patients, dentists should assess recent respiratory-related hospitalization or emergency department visits (e.g., within 3 months), current active respiratory infection (fever, cough, sputum production, wheezing), dyspnea at rest or on minimal exertion, and current medications, particularly inhaled agents, systemic corticosteroids, and anticoagulants.

  • For patients with pulmonary tuberculosis: Disease activity must be assessed prior to any intervention. Patients with active tuberculosis should first receive standardized anti-tuberculosis therapy until sputum bacteriological conversion is attained. Periodontal treatment may only be initiated when the disease is stable, sputum bacteriological results are consistently negative, and non-infectivity is confirmed by a specialist physician.122,123 [B]

Risk stratification and treatment modification

Treatment principles for various respiratory disorders should be followed during periodontal management.30,31 The following modifications to periodontal treatment protocols are stratified by disease type.

Infectious respiratory diseases

  • It is recommended to use antibacterial mouthwash before the procedure to reduce the risk of cross-infection and complications.124,125,126 [A]

  • Ultrasonic scaling and air polishing should be avoided to reduce the risk of aerosol transmission.127 [C]

  • Basic periodontal treatment should be delivered within an isolated setting equipped with strict respiratory isolation measures.128 [B]

COPD

  • Periodontal treatment should be performed gently in separate sessions.128 [B]

  • Treatment should be avoided during acute exacerbations and conducted only after the condition has been stable with confirmation by a respiratory physician. [C]

Asthma

  • Periodontal treatment for asthmatic patients should be conducted during periods of stable condition without signs of acute exacerbation, with avoidance of peak allergic seasons and disease fluctuation phases.129 [B]

  • Anesthetics containing high-concentration epinephrine and allergenic antibiotics should be strictly avoided.129 [B]

Clinical precautions

The following clinical precautions should be observed during periodontal care for patients with respiratory disorders.

  • Oral plaque control: Control of oral plaque is pivotal for inhibiting pneumonia progression.130 For elderly patients, those with neurological disease sequelae, and bedridden patients at risk of aspiration, oral hygiene should be optimized (e.g., chlorhexidine mouthwash administration) prior to invasive oral/periodontal procedures.131 Additionally, professional oral care, including cleaning of teeth, tongue surfaces, and dentures, can effectively reduce oropharyngeal microbial load, thereby mitigating the risk of aspiration pneumonia.132

  • Therapeutic positioning: For patients with respiratory failure, severe asthma, massive pleural effusion, or severe pulmonary arterial hypertension, all basic therapeutic procedures are to be performed gently to minimize airway irritation. A semi-recumbent or sitting position should be prioritized during dental treatment, and a fully supine position should be avoided to prevent postural dyspnea and hemodynamic fluctuations.

Therapeutic benefits

Periodontal treatment was considered positive in reducing the occurrence of respiratory infections such as HAP.133 Although evidence is limited, periodontal treatment was found to effectively improve COPD outcomes, including reducing exacerbations and slowing lung function decline.134 Similarly, in patients without overt pulmonary pathology, lung function was also improved following periodontal therapy.135 In addition, some patients with OSA who use oral appliances or continuous positive airway pressure masks may experience reduced comfort and compliance due to gingival swelling and pain when comorbid with periodontitis. Periodontal treatment can alleviate these symptoms and thereby improve comfort and adherence to OSA therapy, ultimately enhancing treatment outcomes.136

Liver diseases

Background

Liver diseases that are attributed to risk factors such as viral infection and excessive alcohol consumption remain a significant global burden. In 2021, chronic liver disorders affected approximately 1.7 billion individuals worldwide.137 In recent years, the widespread administration of hepatitis B vaccination has contributed to a marked decline in the prevalence of viral hepatitis. Nevertheless, the overall burden of liver diseases remains substantial, with metabolic dysfunction-associated steatotic liver disease (MASLD, the recent replacement term for non-alcoholic fatty liver disease (NAFLD)) emerging as the predominant form of chronic liver disease globally. According to GBD 2023 estimates, MASLD currently affects around 1.3 billion people.138 The latest meta-analysis reported a significant association between periodontitis and MASLD, with a stronger effect size when periodontitis was diagnosed by clinical attachment loss.139

Several mechanisms support the relationship between liver diseases and periodontitis, including systemic inflammation, the colonization of periodontal pathogens through systemic circulation, and oral-gut-liver regulation via gut microbiota and oxidative stress.140,141,142 Periodontitis-driven systemic inflammation can exacerbate hepatic insulin resistance and lipid dysregulation, establishing a metabolic inflammatory loop that links periodontal health to MASLD and its comorbidities (e.g., diabetes and CVDs).143,144

Clinical guidance recommendation

Pretreatment assessment

Owing to various characteristics of liver diseases, such as infectiousness, hemorrhage disorders, and immunosuppression, careful assessment should be taken before and during periodontal management.

  • Patients should be carefully inquired about a history of liver diseases at the first visit. Quantitative determination of HBV (hepatitis B virus)-DNA and HCV (hepatitis C virus)-RNA should be quantified for active hepatitis B and hepatitis C, respectively.145 [B]

  • Coagulation function should also be evaluated, and the treatment principles based on the platelet count are consistent with the abnormal coagulation function mentioned above (Fig. 3). [B]

Risk stratification and treatment modification

According to the patient’s hepatic status, the following modifications to periodontal treatment protocols are recommended.

  • Treatment timing in active viral hepatitis: Periodontal therapy, especially treatment with sonic instruments, should be postponed for patients with active infection of viral hepatitis.145 [B]

  • Treatment modification after transplantation therapy: For patients who have undergone liver transplantation, non-invasive treatments such as supragingival scaling (Step 1) are permissible after 3 months, whereas invasive interventions like subgingival instrumentation (Step 2) require consideration of prophylactic antibiotics even beyond 6 months post-transplantation.146,147 [B]

  • Implant surgery timing after transplantation therapy: To avoid the impact of decreased bone density induced by transplantation surgery, implant surgery should be postponed for at least 12 months.148,149 [C]

Clinical precautions

During periodontal care for patients with liver diseases, the following clinical precautions specific to periodontal procedures should be observed:

  • Cross-infection control: For some acute periodontal infections or persistent gingival bleeding, emergency treatment should be done under the standards for inhibition of cross-infections specific to infectious diseases.

  • Special care for implant surgery: Strict infection control and minimally invasive techniques are recommended to improve success rates and long-term efficacy.148

  • Medication management: Specifically for hepatic dysfunction, adjunctive medication for periodontal treatment should be fully evaluated, such as acetaminophen, tetracyclines, sulfonamides, and fluoroquinolones.30,150,151 Recently, probiotics, prebiotics, and bacteriocins are considered potentially alternative strategies.152

  • Drug-influenced gingival enlargement—surgical timing: Drug-influenced gingival enlargement is regarded as a side effect of immunosuppressive therapy. Step 3 periodontal surgery such as gingivectomy should be postponed until the gingival condition is stable.153

Therapeutic benefits

Despite limited evidence, periodontal therapy has been shown to improve liver disease status. For instance, PMPR was reported to decrease the level of alanine aminotransferase (ALT) and endotoxins in patients with NAFLD.154,155

Kidney diseases

Background

Chronic kidney disease (CKD) refers to the progressive degeneration of kidney function.156 Based on the latest GBD data, CKD is regarded as one of the major global health issues, with 788 million individuals living with CKD in 2023.157 Specific to China, the number of CKD incidence cases was estimated to be 156 million.158 Similar to liver diseases, kidney diseases are also complicated by some shared systemic conditions with periodontitis, such as diabetes and CVDs.156,159

CKD was reported to increase the prevalence of periodontitis.160 A recent cohort study further reported that stage IV periodontitis was independently associated with certain renal function indicators compared with Stage I/II.161 However, the contribution of periodontal infection to all-cause mortality in CKD patients remains to be established.162 Inflammation, oxidative stress, and metabolic derangements are among the putative mechanisms linking periodontitis to kidney diseases.163,164

Clinical guidance recommendation

Pretreatment assessment

For patients with CKD, laboratory parameters of renal function should be assessed prior to periodontal therapy. Given the associated coagulation impairment, platelet count and INR should also be evaluated. The treatment principles are consistent with those for coagulation disorders described above (Fig. 3). [B]

Risk stratification and treatment modification

For kidney transplantation cases, principles of periodontal and implant treatment are similar to patients receiving liver transplantation. Additional modifications to periodontal treatment protocols are recommended as follows.

  • Infection control and systemic benefits: From the perspective of infection control, periodontal therapy was found to be essential not only to improve concurrent diseases such as CVDs, but also to prevent complications induced by kidney transplantation.165,166 Therefore, periodontal treatment is recommended to be carried out prior to dialysis therapy. [C]

  • Medical clearance thresholds: When blood urea nitrogen is above 60 mg/dL and/or serum creatinine is above 1.5 mg/dL, periodontal therapy should be avoided.30 [B]

  • Timing around hemodialysis: It should be noted that special management should be taken in hemodialysis patients who are prone to have hepatitis, anemia, and prolonged hemorrhage. Importantly, periodontal treatment should be applied on the day after dialysis.30 [B]

Clinical precautions

Beyond the procedural modifications above, the following clinical precautions specific to periodontal care should be observed for patients with chronic kidney disease:

  • Raising awareness of periodontal therapy prior to dialysis: Following a comprehensive periodontal evaluation, clinical decision-making should balance infection control with tooth preservation. Although prophylactic extraction of mobile teeth prior to dialysis could minimize perioperative infection risk, this practice should not be applied indiscriminately. Teeth with a favorable prognosis should undergo sequential periodontal treatment in advance if systemic conditions permit, thereby preserving masticatory function and quality of life.167

  • Medication management: With the aim of reducing the metabolic burden on the kidneys, drugs such as phenacetin, tetracycline, and aminoglycoside antibiotics should be avoided. Local anesthesia with lidocaine is considered safe.30

  • Long-term monitoring: Periodontal examination is recommended every 3 to 6 months in patients with CKD.168

Therapeutic benefits

Periodontal treatment has been shown to partially alleviate CKD by reducing the burden of periodontal pathogens, suppressing systemic inflammation, and improving key renal function indicators following PMPR therapy.169,170,171

Cancer

Background

Cancer resulted in approximately 271 million disability-adjusted life-years (DALYs) in the whole world in 2023.172 In 2024, China recorded approximately 5.15 million new cancer cases, representing about 25% of the global total and ranking first in national cancer incidence worldwide.173 Advances in diagnostic and therapeutic technologies have reduced cancer mortality and improved cure rates, while also extending survival for advanced-stage patients. Consequently, the population of individuals with a history of cancer therapy has been steadily growing.

The relationship between periodontitis and certain types of cancer, such as head and neck cancer, digestive tract cancer, lung cancer, and breast cancer, has been studied in recent years. To date, the association between periodontitis and head and neck cancer is supported by the most substantial evidence.174 Dysbiosis of the oral microbiota and systemic inflammation were considered the major mechanisms that supported the association between periodontitis and cancer risk.175,176,177

Clinical guidance recommendation

Pretreatment assessment

  • The type, current phase, and therapeutic dose of oncologic therapy should be assessed. Primary radiation doses above 6000 centigrays (cGy) were associated with a significantly higher incidence of osteoradionecrosis (ORN).178,179,180 [B]

  • Medication history, especially the use of antiresorptive agents, should be carefully inquired.82 Treatment with zoledronate or denosumab for 2 years or longer was found to be associated with an increased risk of MRONJ and should be carefully considered.87 [B]

  • Close attention should be paid to coagulation function by evaluating correlated parameters30,59 (Fig. 3). [B]

Risk stratification and treatment modification

Several principles should be followed to avoid serious complications such as oral infection and ORN.30 To date, the role of pre-oncological periodontal therapy such as Steps 1 and 2 NSPT in oral mucositis remains controversial.181 According to the timeline of oncological therapies, the following modifications to periodontal treatment protocols are stratified as follows:

Before chemotherapy and radiotherapy

  • Uncontrolled periodontal conditions, especially stage Ⅲ–Ⅳ periodontitis, are considered risk factors for ORN.180,182 If tolerated, periodontal treatment should be performed to reduce oral bacterial load and facilitate ORN prevention.30,183 [B]

  • For symptomatic non-vital teeth, endodontic therapy should be completed no later than 7 days prior to the start of radiotherapy, whereas teeth with a poor prognosis should be extracted at least 14 days before radiotherapy.151 [B]

During chemotherapy and radiotherapy

  • Periodontal treatment can be safely performed when the white blood cell count is above 2000/mm3 with absolute neutrophil count (ANC) of 1000 to 1500/mm.3 It should ideally be scheduled on the day before the next chemotherapy cycle.30 [B]

  • During radiotherapy, oral examination is suggested to be conducted weekly to monitor the occurrence of oral mucositis, and periodontal scaling can be taken if clinically indicated.184 [B]

After chemotherapy and radiotherapy

  • Teeth with poor prognosis should not be extracted until at least 6 months after radiotherapy, except in rare circumstances.185 [B]

Before antiresorptive therapies

Cancer and chemotherapy are regarded as risk factors for MRONJ. Further, the dosing intensity and treatment duration of antiresorptive therapy for bone metastasis prevention are far greater than those in the osteoporotic setting. Thus, the risk of MRONJ is significantly higher in patients with malignancies than in those with osteoporosis. In addition, teeth with poor prognosis should also be extracted before antiresorptive therapy.87 [B]

During antiresorptive therapies

  • Oral treatments should be performed with caution during this phase. Tooth extraction, implant surgery, and other dentoalveolar surgeries should be avoided and, where appropriate, replaced with nonsurgical endodontic therapy.151 [B]

  • As in patients with osteoporosis undergoing antiresorptive therapy, drug holidays in patients with malignancies remain controversial87 (Fig. 4). [B]

Clinical precautions

Beyond the procedural modifications above, the following clinical precautions for long-term oral care should be observed for patients who have undergone radiotherapy:

During the first 2–5 years following radiotherapy, when the risk of ORN increases, oral hygiene is particularly important. Chlorhexidine rinses were found beneficial in patients after radiotherapy.186 Meanwhile, regular recall is recommended for long-term management.30,187

Hematological disorders

Background

Hematological disorders refer to a series of complicated blood dysfunctions, such as anemia, leukemia, hemophilia, and agranulocytosis. Accumulating clinical evidence is revealing the potential relationships between hematological disorders and periodontitis.188,189,190,191 Based on a recent experimental study, ligature-induced periodontitis was shown to promote clonal hematopoiesis, a finding that supports a potential mechanistic link between periodontitis and other hematological disorders.192

Manifestations in the gingival tissues, such as a pale and vulnerable appearance, bleeding tendency, gingival overgrowth, and recurrent ulceration, can frequently be the early symptoms of some hematologic diseases.193 Moreover, during periodontal therapy, unrecognized or acute hematological disorders might cause serious complications such as infection of the deep periodontal tissues, post-treatment bleeding, or other life-threatening conditions.194 Therefore, dentists need to be vigilant about the associated oral manifestations and be familiar with the treatment principles for such conditions.

Clinical guidance recommendation

Pretreatment assessment

A comprehensive medical inquiry about history of bleeding following previous injury or surgery is essential to identify hematological conditions or detect potential disorders. For these patients, consultation with a hematologist should be sought from the outset of periodontal management.30 [B]

Risk stratification and treatment modification

The following periodontal procedural modifications are recommended according to different types of hematological disorders.30

Anemia

Hemoglobin (Hb) and Oxygen saturation (SpO2) require close monitoring. Hb < 11 g/dL and SpO2 < 91% indicate unstable conditions in which periodontal therapy should be postponed. Conversely, periodontal treatment can be performed under strict infection control.195 [B]

Agranulocytosis

Hematologists should be consulted, and Steps 1 and 2 NSPT under antibiotic protection can be performed during the remission period.30 [B]

Clinical precautions

For the hematological conditions below, the focus is systemic evaluation and risk control, which should guide the safety, timing, and extent of any necessary periodontal treatment.

Anemia

For some severe types of anemia, such as aplastic anemia, a systematic evaluation of blood parameters and overall systemic conditions should be undertaken before non-surgical or even surgical periodontal treatment.30

Leukemia

For patients with leukemia, special attention should be paid to their high susceptibility to infection, bleeding tendency, and the systemic impact of chemotherapy.

  • ANC should be closely monitored. It is considered a high risk of infection when ANC is below 1 000 per mm3, and antibiotics should be applied before periodontal therapy.59

  • For necessary treatment, platelet transfusion might be applied in advance when platelet counts are below 50 × 109 per L196 (Fig. 3).

  • Considerations for chemotherapy should follow the recommendations for patients with cancer outlined above.

Hemophilia

  • For patients with hemophilia who have abnormal coagulation function and obvious bleeding tendency, Steps 1 and 2 NSPT are more recommended compared to Step 3 periodontal surgery.

  • For Step 3 periodontal surgery, INR should be less than 2–2.5, and the platelet count should be more than 80 × 109 per L. If necessary, antifibrinolytic agents such as local use of tranexamic acid might be applied to prevent peri-treatment bleeding.197

Therapeutic benefits

Periodontal treatments have been proved to be effective on certain types of hematological disorders. From the aspect of inflammation control, NSPT was found to increase the level of Hb in patients with periodontitis who had the tendency of anemia of inflammation.188 For patients with aplastic anemia, NSPT was found to effectively reduce cyclosporine-influenced gingival enlargement with regular return visits and antibiotic protection.198

Conditions with abnormal hormone levels

Abnormal levels of sex steroid hormones

Background

Serving as target sites of sex steroid hormones, periodontal tissues are prone to be affected when sex steroid hormones remain abnormal. Variations in sex hormone levels are closely linked to the severity, progression, and therapeutic outcomes of periodontal diseases by modulating the inflammatory response of periodontal tissues to dental plaque biofilm.26,199

Clinical guidance recommendation

Pretreatment assessment

A specific pretreatment evaluation is required for pregnant patients undergoing periodontal therapy, including precise gestational stage to determine the relatively safe treatment window as well as the necessity of periodontal therapy.30 [B]

Risk stratification and treatment modification

For periodontal patients with abnormal sex hormone levels, extreme caution is advised when performing periodontal therapy during pregnancy.

  • During the first trimester of gestation period: Dental radiography as well as elective mechanical and drug therapy need to be avoided.30 [B]

  • During the second trimester of the gestation period: Step 3 periodontal surgery is suggested to be postponed until after delivery. However, for some emergencies such as pregnancy epulis which cause difficulty in mastication or persistent gingival bleeding, gingivectomy can be carried out.30 [B]

Clinical precautions

Periodontal management should be adjusted in response to the regulation of sex steroid hormones during different physiological cycles.30,200

Puberty

Adolescents usually exhibit heightened gingival sensitivity to plaque accumulation. Steps 1 and 2 NSPT are essential to remove plaque stimulation, which will control gingival inflammation. For the remaining overgrown gingival tissue as well as fibrous hyperplasia, gingivectomy and gingivoplasty (Step 3) can be performed. It should be emphasized that good oral hygiene and regular PMPR (Step 1) are necessary for adolescents, especially before and during orthodontic treatment.

Menstrual period

The menstrual period is not considered a contraindication to periodontal therapy. Necessary treatment can be safely performed provided that pain management, infection prevention, and control of excessive gingival bleeding are ensured.

Preconception period

Women in the preconception period should be educated about the importance and necessity of periodontal health since the progression or severity of gingival inflammation as the fluctuation of hormones in the gestation period, is closely related to periodontal status before pregnancy. Meanwhile, Steps 1 and 2 NSPT, as well as necessary surgical treatment (Step 3) need to be carried out.

Gestation period

  • The first trimester: Periodontal treatment during the first trimester should be performed with extreme prudence.

  • The second trimester: The second trimester is regarded as a relatively safe period, during which routine dental care such as Step 1 PMPR can be performed to control active infection. Though not recommended, necessary dental radiographs (e.g., bitewing, panoramic, or selected periapical films) can be taken under the protection of lead aprons. For acute inflammatory conditions, such as periodontal abscesses, necessary medications can be used, provided that their potential side effects on both the pregnant woman and the fetus are fully considered.

  • The third trimester: For the reason that the uterus is sensitive to mechanical stimuli, periodontal treatment should also be performed prudently, especially in the last half of the third trimester to prevent preterm delivery. Meanwhile, attention should be paid to supine hypotensive syndrome.

  • Lactation period: Periodontal therapy is considered safe after birth-delivery. For essential drug therapy, the prescribed drugs need to be taken just after breastfeeding and sustained for at least 4 h before the next feeding.

Thyroid disorders

Background

The thyroid is the largest endocrine gland with multiple functions in physiological regulation. Thyroid disorders mainly include functional disorders (e.g., hypothyroidism and hyperthyroidism), structural disorders (e.g., thyroid nodules), thyroiditis (e.g., Hashimoto’s thyroiditis), and thyroid tumors. Nowadays, more and more people suffer from thyroid disorders, and thyroid cancer has become the most common endocrine malignancy worldwide.201 In China, the cases of thyroid cancer per 100 000 people in 1990 were 0.87, while the data significantly increased to 3.88 in 2021. High BMI was found to be a major risk factor for thyroid cancer in China.202

Despite the insufficient clinical evidence, the potential relationship between periodontitis and thyroid dysfunction has been revealed.203 It was recently found that the prevalence and severity of periodontitis were increased in patients with autoimmune hypothyroidism, and thyroid parameters such as thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4) were positively associated with periodontal parameters.204 Moreover, TSH might be applied as a potential predictor for periodontitis.205 Generally, systemic inflammation and abnormal bone metabolism are considered the major mechanisms related to the association between periodontitis and thyroid disorders.206,207

Clinical guidance recommendation

Pretreatment assessment

For patients with thyroid disorders, the stability of thyroid parameters such as TSH, T3, and T4 should be evaluated.30 [B]

Risk stratification and treatment modification

Based on the above assessment, the following periodontal procedural considerations apply:

  • Periodontal treatment is generally considered safe for individuals with thyroid disorders.30 [B]

  • Periodontal therapy should be deferred for patients with uncontrolled thyrotoxicosis.30 [B]

Clinical precautions

Medication considerations: Due to thyroid dysfunction, certain medicines need to be carefully applied during periodontal therapy. For patients with thyrotoxicosis or poorly controlled thyroid disorders, vasopressor amines such as epinephrine should be avoided. For patients with hyperthyroidism, the dosage of these medicines needs to be evaluated to prevent possible cardiovascular disorders, such as increased cardiac output and myocardial ischemia.30

Therapeutic benefits

The positive role of periodontal therapy in thyroid disorders has been reported by limited studies. In hypothyroid patients with periodontitis, the level of TSH was significantly reduced after 3 months following NSPT.208 More clinical studies are needed to explore the effect of periodontal therapy on the regulation of thyroid function.

Conclusions and future perspectives

In conclusion, this expert consensus reframes periodontitis management for medically complex patients as a dynamic, risk-stratified process that is tightly aligned with the individual’s medical status and treatment course. At its core, from initial debridement to surgical planning, clinical decision-making hinges on a baseline safety appraisal encompassing hemorrhagic risk, immune competence, and major organ reserve (i.e., metabolic, excretory, hemodynamic, and skeletal remodeling capacities), since these domains collectively define the risk assessment for dental intervention. Accordingly, the proposed strategy adopts a sequenced approach to treatment planning: non-surgical therapy proceeds with routine mechanical measures, coupled with dose vigilance for any adjunctive drugs according to organ function, whereas surgical phases are intentionally postponed until medical stability is formally confirmed. Equally importantly, the long-term supportive care plan has been shifted from fixed-interval recall to adaptive recall intervals, with re-evaluation prompted by any significant change in the patient’s comorbidity status or medication profile. Taken together, these practical principles constitute a pragmatic, safety-oriented framework that prioritizes patient stability over procedural convenience.

Future research should address several priorities. First, epidemiological evidence remains incomplete for certain periodontitis–systemic disease associations, warranting large-scale studies with rigorous phenotyping. Second, clinical decision-making for patients with systemic conditions relies largely on observational studies of low evidentiary strength; well-powered randomized trials, pragmatic multi-center designs, and condition-specific registries are therefore urgently needed. Third, chairside biomarker testing capable of monitoring both oral and systemic disease activity warrants prospective validation to support more tailored clinical decisions. Until such evidence emerges, this consensus recommends that clinical decisions be individualized through close dental–medical collaboration and careful systemic risk assessment. Bridging these gaps will require sustained interdisciplinary effort, but the principles outlined here offer a practical framework for care in the interim.

References

  1. Nascimento, G. G., Alves-Costa, S. & Romandini, M. Burden of severe periodontitis and edentulism in 2021, with projections up to 2050: The Global Burden of Disease 2021 study. J. Periodontal Res. 59, 823–867 (2024).

    PubMed  Google Scholar 

  2. Zhang, K., Ma, Y., Shi, J. & Geng, Y. Epidemiological trends and incidence prediction of periodontal disease based on the Global Burden of Disease study 2021. Front. Dent. Med. 6, 1643049 (2025).

    PubMed  PubMed Central  Google Scholar 

  3. Zhou, M. et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 394, 1145–1158 (2019).

    PubMed  PubMed Central  Google Scholar 

  4. The Global Burden of Disease, Injury and Risk Factor Collaborators Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1873–1922 (2025).

  5. Romandini, M., Hajishengallis, G., Curtis, M. & Baima, G. Periodontal medicine rewired: mechanisms linking periodontitis to systemic diseases. J. Periodontal Res. 0, 1–42 (2026).

  6. Loos, B. G. & Van Dyke, T. E. The role of inflammation and genetics in periodontal disease. Periodontology 83, 26–39 (2020).

    Google Scholar 

  7. Villoria, G. E. M., Fischer, R. G., Tinoco, E. M. B., Meyle, J. & Loos, B. G. Periodontal disease: a systemic condition. Periodontology 96, 7–19 (2024).

    Google Scholar 

  8. Tonetti, M. S., Jepsen, S., Jin, L. & Otomo-Corgel, J. Impact of the global burden of periodontal diseases on health, nutrition and wellbeing of mankind: a call for global action. J. Clin. Periodontol. 44, 456–462 (2017).

    PubMed  Google Scholar 

  9. Li, X. et al. Maladaptive innate immune training of myelopoiesis links inflammatory comorbidities. Cell 185, 1709–1727.e1718 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Jin, W. et al. The oral - X axis: from periodontal dysbiosis to systemic disease. Front. Immunol. 17, 1806445 (2026).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Romandini, M. et al. Periodontitis, edentulism, and risk of mortality: a systematic review with meta-analyses. J. Dent. Res. 100, 37–49 (2021).

    CAS  PubMed  Google Scholar 

  12. Marruganti, C., Suvan, J. E. & D’Aiuto, F. Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity. Periodontology 2000 00, 1–16 (2023).

  13. Juni, P. et al. 2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention. Eur. Heart J. 46, 1885–1894 (2025).

    PubMed  Google Scholar 

  14. van der Wal, H. et al. Development of a set of patient-centred outcome measures for patients with major injury: Delphi-based consensus recommendations from the International Consortium for Health Outcomes Measurement Major Injury Working Group. EClinicalMedicine 90, 103617 (2025).

    PubMed  PubMed Central  Google Scholar 

  15. Sanz, M. et al. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. J. Clin. Periodontol. 45, 138–149 (2018).

    CAS  PubMed  Google Scholar 

  16. Chinese Stomatological, A. [Consensus of Chinese stomatological multidisciplinary experts on maintaining periodontal health (First edition)]. Zhonghua Kou Qiang Yi Xue Za Zhi 56, 127–135 (2021).

    Google Scholar 

  17. Genitsaridi, I. et al. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diab Endocrinol. 14, 149–156 (2026).

    Google Scholar 

  18. Deng, W. et al. National burden and risk factors of diabetes mellitus in China from 1990 to 2021: Results from the Global Burden of Disease study 2021. J. Diab 16, e70012 (2024).

    Google Scholar 

  19. Wang, L. et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317, 2515–2523 (2017).

    PubMed  PubMed Central  Google Scholar 

  20. Wang, L. et al. Prevalence and Treatment of Diabetes in China, 2013-2018. JAMA 326, 2498–2506 (2021).

    PubMed  PubMed Central  Google Scholar 

  21. Papapanou, P. N. et al. Periodontitis: consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J. Clin. Periodontol. 45, S162–S170 (2018).

    PubMed  Google Scholar 

  22. Botelho, J. et al. Oral health and diabetes: a systematic review and meta-analysis. Lancet Public Health 11, e555-e566 (2026).

  23. Edgar, L. et al. Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis. Circulation 144, 961–982 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Barutta, F., Bellini, S., Durazzo, M. & Gruden, G. Novel insight into the mechanisms of the bidirectional relationship between diabetes and periodontitis. Biomedicines 10, 178 (2022).

  25. Zhu, Y. et al. The role of PKM2-mediated metabolic reprogramming in the osteogenic differentiation of BMSCs under diabetic periodontitis conditions. Stem Cell Res. Ther. 16, 186 (2025).

    Article  CAS  PubMed  Google Scholar 

  26. Sanz, M. et al. Treatment of stage I-III periodontitis-the EFP S3 level clinical practice guideline. J. Clin. Periodontol. 47, 4–60 (2020).

    PubMed  PubMed Central  Google Scholar 

  27. Society, C. D. Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition). Chin. J. Diab Mellit. 17, 16–139 (2025).

    Google Scholar 

  28. Yan, F. & Chen, F. Periodontology, 6th edn (People’s Medical Publishing House, 2025).

  29. Graziani, F. et al. Acute-phase response following one-stage full-mouth versus quadrant non-surgical periodontal treatment in subjects with comorbid type 2 diabetes: a randomized clinical trial. J. Clin. Periodontol. 50, 487–499 (2023).

    CAS  PubMed  Google Scholar 

  30. Michael G. Newman, P. R. K., Satheesh Elangovan, Yvonne Kapila. Newman and Carranza’s Clinical Periodontology and Implantology, 14th edn (Saunders Elsevier, 2023).

  31. Herrera, D. et al. Association between periodontal diseases and cardiovascular diseases, diabetes and respiratory diseases: Consensus report of the Joint Workshop by the European Federation of Periodontology (EFP) and the European arm of the World Organization of Family Doctors (WONCA Europe). J. Clin. Periodontol. 50, 819–841 (2023).

    CAS  PubMed  Google Scholar 

  32. Askar, H. et al. Incidence and severity of postoperative complications following oral, periodontal, and implant surgeries: a retrospective study. J. Periodontol. 90, 1270–1278 (2019).

    PubMed  Google Scholar 

  33. Al-Abbadi, R., Shemais, N., Nawwar, A. & Fawzy El-Sayed, K. M. Non-surgical periodontal therapy with and without hyaluronic acid gel in type 2 diabetic stage-II periodontitis patients: a randomized clinical trial. BMC Oral. Health 25, 1166 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  34. Yuqi, W., Hangying, X., Ruyi, Y., Xiaolan, Z. & Yajing, C. Effectiveness of probiotic therapy as an adjunct in the management of periodontal disease in type 2 diabetics: a systematic review and meta-analysis. Diab Res Clin. Pr. 226, 112358 (2025).

    Google Scholar 

  35. Xu, X. et al. Potential short-term shift in oral microbiota of patients with stage III-IV periodontitis and type 2 diabetes treated by non-surgical periodontal therapy. J. Dent. Sci. 20, 1470–1479 (2025).

    PubMed  PubMed Central  Google Scholar 

  36. D’Aiuto, F. et al. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diab Endocrinol. 6, 954–965 (2018).

    Google Scholar 

  37. Raedel, M., Noack, B., Priess, H. W., Bohm, S. & Walter, M. H. Massive data analyses show negative impact of type 1 and 2 diabetes on the outcome of periodontal treatment. Clin. Oral. Investig. 25, 2037–2043 (2021).

    PubMed  Google Scholar 

  38. Ren, L., Fu, Y., Deng, Y., Qi, L. & Jin, L. Advanced glycation end products inhibit the expression of collagens type I and III by human gingival fibroblasts. J. Periodontol. 80, 1166–1173 (2009).

    CAS  PubMed  Google Scholar 

  39. Zhao, P. et al. Hyperglycaemia-associated macrophage pyroptosis accelerates periodontal inflamm-aging. J. Clin. Periodontol. 48, 1379–1392 (2021).

    CAS  PubMed  Google Scholar 

  40. Zhang, M. et al. Photoacoustic imaging-guided self-adaptive hyperthermia supramolecular cascade nano-reactor for diabetic periodontal bone regeneration. Adv. Sci. (Weinh.) 11, e2404143 (2024).

    PubMed  PubMed Central  Google Scholar 

  41. Xiang, D. D. et al. Diabetes and periodontitis: the role of a high-glucose microenvironment in periodontal tissue cells and corresponding therapeutic strategies. Stem Cell Res. Ther. 16, 366 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  42. Duman, I., Tanriverdi, G. & Ozturk Ozener, H. Effects of vitamin K2 administration on guided bone regeneration in diabetic rats. J. Periodontal Res. 59, 993–1004 (2024).

    CAS  PubMed  Google Scholar 

  43. Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. J. Am. Coll. Cardiol. 86, 2167–2243 (2025).

  44. In China, T. & Hu, S. S. Report on cardiovascular health and diseases in China 2021: an updated summary. J. Geriatr. Cardiol. 20, 399–430 (2023).

    PubMed  Google Scholar 

  45. Alam, M. K. et al. Periodontitis as an independent risk factor for cardiovascular disease: a systematic review and meta-analysis. BMC Oral Health 26, 1783 (2026).

  46. Wang, J. et al. Hypertensive patients with periodontitis as predictors of cardiovascular and all-cause mortality: a long-term cohort study. Clin. Oral. Investig. 28, 582 (2024).

    PubMed  Google Scholar 

  47. Wu, Y. et al. Alterations in the salivary microbiome and metabolism in patients with carotid atherosclerosis from rural Northeast China. J. Am. Heart Assoc. 13, e034014 (2024).

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Xu, T. et al. Porphyromonas gingivalis infection promotes mitochondrial dysfunction through Drp1-dependent mitochondrial fission in endothelial cells. Int J. Oral Sci. 13, 28 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Herrera, D., Molina, A., Buhlin, K. & Klinge, B. Periodontal diseases and association with atherosclerotic disease. Periodontology 83, 66–89 (2020).

    Google Scholar 

  50. Mitroulis, I., Hajishengallis, G. & Chavakis, T. Bone marrow inflammatory memory in cardiometabolic disease and inflammatory comorbidities. Cardiovasc. Res. 119, 2801–2812 (2024).

    PubMed  PubMed Central  Google Scholar 

  51. Ishai, A. et al. Periodontal disease associates with arterial inflammation via potentiation of a hematopoietic-arterial axis. JACC Cardiovasc. Imaging 12, 2271–2273 (2019).

    PubMed  PubMed Central  Google Scholar 

  52. Li, E., Huang, J., Yao, J., Lei, M. & Wu, M. Oral microbiota dysbiosis and the oral-X axis in chronic diseases. Genes Diseases 102274 https://doi.org/10.1016/j.gendis.2026.102274 (2026).

  53. Chinese Society of Cardiology, C. M. A., Hypertension Committee of Cross-Straits Medicine Exchange, A., Cardiovascular Disease, P. & Rehabilitation Committee, C. A. o. R. M. [Clinical practice guidelines for the management of hypertension in China]. Zhonghua Xin Xue Guan Bing Za Zhi 52, 985–1032 (2024).

  54. Song, J.-C. et al. Chinese expert consensus on standardized assessment of severe coagulopathy (2025 edition). Med. J. Chin. People’s Lib. Army 50, 1055–1069 (2025).

  55. Sanz, M. et al. Periodontitis and cardiovascular diseases: Consensus report. J. Clin. Periodontol. 47, 268–288 (2020).

    PubMed  PubMed Central  Google Scholar 

  56. Orlandi, M., Graziani, F. & D’Aiuto, F. Periodontal therapy and cardiovascular risk. Periodontology 83, 107–124 (2020).

    Google Scholar 

  57. Lombardi, N., Varoni, E. M., Sorrentino, D. & Lodi, G. International normalized ratio (INR) values in patients receiving oral vitamin K antagonists and undergoing oral surgery: a clinical audit. Spec. Care Dent. 40, 374–381 (2020).

    Google Scholar 

  58. Chinese Society of Emergency Medicine (CSEM), Chinese Medical Doctors Association of Interventional, D., Hemorrhage Professional Committee of Chinese Research Hospital, A. & Chinese Federation of the Hemorrhage, C. [Expert consensus on critical values of hemorrhagic diseases (2023 version)]. Zhonghua Nei Ke Za Zhi 62, 939–948 (2023).

  59. Mealey, B. L. Periodontal implications: medically compromised patients. Ann. Periodontol. 1, 256–321 (1996).

    CAS  PubMed  Google Scholar 

  60. Wilson, W. R. et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the american heart association. Circulation 143, e963–e978 (2021).

    PubMed  Google Scholar 

  61. Delgado, V. et al. 2023 ESC Guidelines for the management of endocarditis. Eur. Heart J. 44, 3948–4042 (2023).

    PubMed  Google Scholar 

  62. Iijima, Y. et al. Persistent gingival bleeding related to periodontal disease. Cureus 17, e77693 (2025).

    PubMed  PubMed Central  Google Scholar 

  63. Drozdzik, A. & Drozdzik, M. Drug-induced gingival overgrowth-molecular aspects of drug actions. Int. J. Mol. Sci. 24, 5448 (2023).

  64. Seymour, R. A., Ellis, J. S. & Thomason, J. M. Risk factors for drug-induced gingival overgrowth. J. Clin. Periodontol. 27, 217–223 (2000).

    CAS  PubMed  Google Scholar 

  65. Mavrogiannis, M., Ellis, J. S., Seymour, R. A. & Thomason, J. M. The efficacy of three different surgical techniques in the management of drug-induced gingival overgrowth. J. Clin. Periodontol. 33, 677–682 (2006).

    CAS  PubMed  Google Scholar 

  66. Ikawa, K., Ikawa, M., Shimauchi, H., Iwakura, M. & Sakamoto, S. Treatment of gingival overgrowth induced by manidipine administration. A case report. J. Periodontol. 73, 115–122 (2002).

    PubMed  Google Scholar 

  67. Morikawa, S., Nasu, M., Miyashita, Y. & Nakagawa, T. Treatment of calcium channel blocker-induced gingival overgrowth without modifying medication. BMJ Case Rep. 14, e238872 (2021).

  68. Tonetti, M. S. et al. Treatment of periodontitis and endothelial function. N. Engl. J. Med. 356, 911–920 (2007).

    CAS  PubMed  Google Scholar 

  69. Bechina, C. et al. Effects of periodontal therapy on cardiovascular risk biomarkers: a systematic review. Oral. Health Prev. Dent. 23, 457–467 (2025).

    PubMed  PubMed Central  Google Scholar 

  70. Gandhi, K. K., Batra, C. & Affendi, H. Cardiovascular and anti-inflammatory effects of periodontal therapy: a systematic review and meta-analysis of randomized trials. J. Periodontol. 1–24 (2026). (Online ahead of print).

  71. Xu, S. et al. Alleviate periodontitis and its comorbidity hypertension using a nanoparticle-embedded functional hydrogel system. Adv. Health Mater. 12, e2203337 (2023).

    Google Scholar 

  72. Salari, N. et al. Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J. Orthop. Surg. Res. 16, 669 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  73. Wang, L. et al. Prevalence of osteoporosis and fracture in China: the China osteoporosis prevalence study. JAMA Netw. Open 4, e2121106 (2021).

    PubMed  PubMed Central  Google Scholar 

  74. Penoni, D. C. et al. Bone density and clinical periodontal attachment in postmenopausal women: a systematic review and meta-analysis. J. Dent. Res. 96, 261–269 (2017).

    CAS  PubMed  Google Scholar 

  75. Joseph, B. et al. Low bone density and periodontal disease in postmenopausal women: a systematic review and meta-analysis. J. Fam. Med. Prim. Care 14, 4955–4966 (2025).

    Google Scholar 

  76. Chang, J., Bhuvanagiri, G. M., Dulkanchainun, M. & Wang, C. Osteoporosis and periodontitis: two-way epidemiological and mechanistic evidence. J. Periodontal. Res. 0, 1–29 (2026).

  77. Haacke, N. et al. Innate immune training of osteoclastogenesis promotes inflammatory bone loss in mice. Dev. Cell 60, 1854–1870.e1856 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Yu, B. & Wang, C. Y. Osteoporosis and periodontal diseases - an update on their association and mechanistic links. Periodontology 89, 99–113 (2022).

    Google Scholar 

  79. Wang, N. et al. Periodontitis-associated salivary microbiota exacerbates systemic osteoclastogenesis via gut modulation and tryptophan metabolism suppression in ovariectomized mice. Int J. Oral Sci. 18, 14 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  80. Omelchenko, V. et al. Modern strategies for osteoporosis therapy: current status and prospects for targeted intervention. Int. J. Mol. Sci. 26, 11092 (2025).

  81. Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral. Maxillofac. Surg. 72, 1938–1956 (2014).

    PubMed  Google Scholar 

  82. Chen, T. Y. et al. Medication-related osteonecrosis of the jaw following osteoporosis therapy: a real-world retrospective cohort study using the TriNetX global collaborative network. Bone 202, 117678 (2026).

    CAS  PubMed  Google Scholar 

  83. Hu, H. T. et al. Emerging regulated cell death mechanisms in bone remodeling: decoding ferroptosis, cuproptosis, disulfidptosis, and PANoptosis as therapeutic targets for skeletal disorders. Cell Death Discov. 11, 335 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  84. Chen, R. et al. Non-surgical periodontal therapy and metformin improve bone loss in obese mice with periodontitis by modulating the gut microbiota. FASEB J. 39, e70814 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Snyder, S. Postmenopausal osteoporosis. N. Engl. J. Med. 390, 675–676 (2024).

    PubMed  Google Scholar 

  86. Morin, S. N., Leslie, W. D. & Schousboe, J. T. Osteoporosis: a review. JAMA 334, 894–907 (2025).

  87. Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update. J. Oral. Maxillofac. Surg. 80, 920–943 (2022).

    PubMed  Google Scholar 

  88. Wick, A. et al. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. Clin. Oral. Investig. 26, 2839–2852 (2022).

    PubMed  Google Scholar 

  89. Lorenzo-Pouso, A. I. et al. Association between periodontitis and medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J. Oral. Pathol. Med. 49, 190–200 (2020).

    PubMed  Google Scholar 

  90. Troeltzsch, M. et al. Chronic periodontal infection and not iatrogenic interference is the trigger of medication-related osteonecrosis of the jaw: insights from a large animal study (PerioBRONJ Pig Model). Medicina 59, 1000 (2023).

  91. Bujila, A. et al. Peri-implant inflammation increases the risk of osteonecrosis in mice treated with bisphosphonate. J. Periodontol. 96, 894–905 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Ali, D. S. et al. Antiresorptive therapy to reduce fracture risk and effects on dental implant outcomes in patients with osteoporosis: a systematic review and osteonecrosis of the jaw taskforce consensus statement. Endocr. Pr. 31, 686–698 (2025).

    Google Scholar 

  93. Li, J. T. W. & Leung, Y. Y. Effect of antiresorptive drugs on osseointegrated dental implants: a systematic review. J. Clin. Med. 13, 2091 (2024).

  94. Pruthi, G. Risk of medication-related osteonecrosis of the jaws (MRONJ) in osteoporotic patients treated with antiresorptive drug therapy and dental implants. Evid. Based Dent. 27, 46–48 (2026).

  95. Diniz-Freitas, M., Fernandez-Feijoo, J., Diz Dios, P., Pousa, X. & Limeres, J. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: a case report. J. Clin. Periodontol. 45, 570–577 (2018).

    PubMed  Google Scholar 

  96. Miron, R. J. et al. Autogenous platelet concentrates for treatment of intrabony defects-a systematic review with meta-analysis. Periodontol 2000 97, 153–190 (2025).

    PubMed  Google Scholar 

  97. Miron, R. J. et al. Periodontal regeneration using platelet-rich fibrin. Furcation defects: a systematic review with meta-analysis. Periodontol 2000 97, 191–214 (2025).

    PubMed  Google Scholar 

  98. Zhao, Y., Lan, W., Zhang, L., Xu, D. & Wang, C. Research progress on ROS-responsive hydrogels for the treatment of osteoporosis: a review. Biomed. Mater. 21, 022007 (2026).

  99. Zhu, Y. et al. Injectable hydrogels with ROS-triggered drug release enable the co-delivery of antibacterial agent and anti-inflammatory nanoparticle for periodontitis treatment. J. Nanobiotechnol. 23, 205 (2025).

    Article  CAS  Google Scholar 

  100. Passos-Soares, J. S. et al. Association between osteoporosis treatment and severe periodontitis in postmenopausal women. Menopause 24, 789–795 (2017).

    PubMed  Google Scholar 

  101. Oh, J. et al. Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990-2023: a Global Burden of Disease study. Nat. Med. 32, 197–223 (2026).

    Article  CAS  PubMed  Google Scholar 

  102. Yin, Y., Lin, X., Zhong, W., Chen, T. & Chen, J. Burden of chronic respiratory disease in Fujian province, 1990-2021. PLoS ONE 20, e0335352 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  103. de Melo Neto, J. P. et al. Periodontal infections and community-acquired pneumonia: a case-control study. Eur. J. Clin. Microbiol. Infect. Dis. 32, 27–32 (2013).

    Article  CAS  PubMed  Google Scholar 

  104. Gomes-Filho, I. S. et al. Influence of periodontitis in the development of nosocomial pneumonia: a case control study. J. Periodontol. 85, e82–90 (2014).

    PubMed  Google Scholar 

  105. Scannapieco, F. A. & Ho, A. W. Potential associations between chronic respiratory disease and periodontal disease: analysis of National Health and Nutrition Examination Survey III. J. Periodontol. 72, 50–56 (2001).

    CAS  PubMed  Google Scholar 

  106. Prasanna, S. J. Causal relationship between periodontitis and chronic obstructive pulmonary disease. J. Indian Soc. Periodontol. 15, 359–365 (2011).

    PubMed  PubMed Central  Google Scholar 

  107. Bianchi, E. et al. Relationship between periodontal disease and obstructive sleep apnea in adults: a systematic review. Dent. Res J. 21, 15 (2024).

    Google Scholar 

  108. Chen, X., Wu, L., Wu, R. & Dong, J. A pulmonary abscess caused by Porphyromonas gingivalis infection: a case report and literature review. Clin. Respir. J. 19, e70099 (2025).

    PubMed  PubMed Central  Google Scholar 

  109. Ye, H. L. et al. Periodontitis aggravates pulmonary fibrosis by Porphyromonas gingivalis-promoted infiltration of neutrophils and Th17 cells. Front. Cell Infect. Microbiol. 15, 1595500 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Sivaramakrishnan, G. & Sridharan, K. Linking lungs and gums: a meta-analysis of periodontitis prevalence and severity in chronic obstructive pulmonary disease. BDJ Open 12, 16 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  111. Saleh, M. H. A. et al. Association between asthma and periodontitis: a case-control analysis of risk factors, related medications, and allergic responses. J. Periodontal Res. 60, 44–54 (2025).

    PubMed  Google Scholar 

  112. Scannapieco, F. A. Poor oral health in the etiology and prevention of aspiration pneumonia. Clin. Geriatr. Med. 39, 257–271 (2023).

    PubMed  Google Scholar 

  113. Herrera, D. et al. Periodontal diseases and cardiovascular diseases, diabetes, and respiratory diseases: Summary of the consensus report by the European Federation of Periodontology and WONCA Europe. Eur. J. Gen. Pr. 30, 2320120 (2024).

    Google Scholar 

  114. Tan, L., Tang, X., Pan, C., Wang, H. & Pan, Y. Relationship among clinical periodontal, microbiologic parameters and lung function in participants with chronic obstructive pulmonary disease. J. Periodontol. 90, 134–140 (2019).

    PubMed  Google Scholar 

  115. Pinto, G. R. et al. Subgingival biofilm microbiome in individuals with asthma and periodontitis: Metagenomic analysis. Oral. Dis. 30, 4721–4730 (2024).

    PubMed  Google Scholar 

  116. Nagaoka, K. et al. Quantitative detection of periodontopathic bacteria in lower respiratory tract specimens by real-time PCR. J. Infect. Chemother. 23, 69–73 (2017).

    PubMed  Google Scholar 

  117. Guo, N. et al. Metagenomic next-generation sequencing reveals porphyromonas gingivalis in geriatric severe pneumonia complicated by empyema: case report. Infect. Drug Resist. 18, 4811–4816 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  118. Zhang, L. et al. Periodontitis pathogen Porphyromonas gingivalis promotes chronic obstructive pulmonary disease via affecting neutrophils chemotaxis and function. Int J. Oral. Sci. 18, 4 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  119. Li, Q. et al. Fusobacterium nucleatum interaction with Pseudomonas aeruginosa induces biofilm-associated antibiotic tolerance via Fusobacterium adhesin A. ACS Infect. Dis. 6, 1686–1696 (2020).

    CAS  PubMed  Google Scholar 

  120. Zhao, Q. et al. Porphyromonas gingivalis inducing autophagy-related biological dysfunction in alveolar epithelial cells: an in vitro study. BMC Oral. Health 24, 1478 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Miya, C. et al. Porphyromonas gingivalis gingipains potentially affect MUC5AC gene expression and protein levels in respiratory epithelial cells. FEBS Open Biol. 11, 446–455 (2021).

    CAS  Google Scholar 

  122. Clinical Research Center for Infectious Disease, the Third People's Hospital of Shenzhen, Editorial Board of Chinese Journal of Antituberculosis National Expert consensus on a standard of activity judgment of pulmonary tuberculosis and its clinical implementation. Chin. J. Antituberc. 42, 301–307 (2020).

  123. Cleveland, J. L., Robison, V. A. & Panlilio, A. L. Tuberculosis epidemiology, diagnosis and infection control recommendations for dental settings: an update on the Centers for Disease Control and Prevention guidelines. J. Am. Dent. Assoc. 140, 1092–1099 (2009).

    PubMed  Google Scholar 

  124. Koletsi, D., Belibasakis, G. N. & Eliades, T. Interventions to reduce aerosolized microbes in dental practice: a systematic review with network meta-analysis of randomized controlled trials. J. Dent. Res. 99, 1228–1238 (2020).

    CAS  PubMed  Google Scholar 

  125. Zhou, Q. et al. Comparative efficacy of preprocedural mouthwashes in reducing microbial aerosols during dental procedures: a network meta-analysis. Infect. Dis. Health 31, 100426 (2026).

    PubMed  Google Scholar 

  126. Saini, R. S., Binduhayyim, R. I. H., Mosaddad, S. A. & Heboyan, A. Strategies for preventing aerosol-generated microbial contamination in dental procedures: a systematic review and meta-analysis. Am. J. Infect. Control 53, 638–647 (2025).

    CAS  PubMed  Google Scholar 

  127. Goncalves Lomardo, P. et al. Concern about the risk of aerosol contamination from ultrasonic scaler: a systematic review and meta-analysis. BMC Oral. Health 24, 417 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  128. Wang, Z. M. et al. Consensus of experts on the oral health management and medical risk prevention for the patients with chronic airway diseases (2022 edition). Zhonghua Kou Qiang Yi Xue Za Zhi 57, 455–461 (2022).

    CAS  PubMed  Google Scholar 

  129. Wang, Z. M. et al. Consensus of experts on the oral health management and medical risk prevention for the patients with chronic airway diseases (2022 edition). Chin. J. Stomatol 57, 455–461 (2022).

    CAS  Google Scholar 

  130. Kim, S. J. et al. Chronic periodontitis and community-acquired pneumonia: a population-based cohort study. BMC Pulm. Med. 19, 268 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Klompas, M., Speck, K., Howell, M. D., Greene, L. R. & Berenholtz, S. M. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-analysis. JAMA Intern Med. 174, 751–761 (2014).

    CAS  PubMed  Google Scholar 

  132. Fischer, R. G. et al. What is the future of periodontal medicine? Braz. Oral. Res. 35, e102 (2021).

    PubMed  Google Scholar 

  133. Baker, D. et al. The association between accessing dental services and nonventilator hospital-acquired pneumonia among 2019 Medicaid beneficiaries. Infect. Control Hosp. Epidemiol. 44, 959–961 (2023).

    PubMed  Google Scholar 

  134. Apessos, I., Voulgaris, A., Agrafiotis, M., Andreadis, D. & Steiropoulos, P. Effect of periodontal therapy on COPD outcomes: a systematic review. BMC Pulm. Med. 21, 92 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  135. Rosland, A. et al. Effect of periodontal therapy on lung function: a twelve-month follow-up intervention study. Respir. Res. 26, 172 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  136. Ramar, K. et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. J. Clin. Sleep. Med. 11, 773–827 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  137. Zhang, Y., Luo, M. & Ming, Y. Global burden of cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2021. BMC Gastroenterol. 25, 641 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  138. Collaborators, G. M. Global burden of metabolic dysfunction-associated steatotic liver disease, 1990-2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Gastroenterol. Hepatol. 11, 463–494 (2026).

    Google Scholar 

  139. Li, H., Shi, M., Yuan, R., Wang, H. & Li, Y. Association between periodontitis and non-alcoholic fatty liver disease in community-dwelling adults: a systematic review and meta-analysis. Sci. Rep. 16, 16217 (2026).

  140. Kuraji, R., Sekino, S., Kapila, Y. & Numabe, Y. Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an emerging concept of oral-liver axis. Periodontol 2000 87, 204–240 (2021).

    PubMed  PubMed Central  Google Scholar 

  141. Vegda, H. S. et al. Role of nonalcoholic fatty liver disease in periodontitis: a bidirectional relationship. Cureus 16, e63775 (2024).

    PubMed  PubMed Central  Google Scholar 

  142. Juzbasic, M. et al. Interaction between periodontitis and MASLD: pathophysiological associations and possibilities of prevention and therapy. Biomedicines 13, 1346 (2025).

  143. Wang, M. et al. Periodontitis salivary microbiota exacerbates nonalcoholic fatty liver disease in high-fat diet-induced obese mice. iScience 26, 106346 (2023).

    CAS  PubMed  PubMed Central  Google Scholar 

  144. Jin, Y. et al. The triadic relationship between nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease: From molecular mechanisms to clinical management. Curr. Probl. Cardiol. 50, 103170 (2025).

    PubMed  Google Scholar 

  145. Management, Clinical Studies on Hepatitis (CSH), and Hepatology within the context of a Contract Research Organization (CRO) or Chief Scientific Officer (CSO). Expert consensus on viral hepatitis health management (2021). Chin. J. Health Manag. 15, 323–331 (2021).

  146. Krishnamurthy Bonanthaya, E. P., Suvy Manuel, Vinay V. Kumar, Anshul Rai (eds). in Oral and Maxillofacial Surgery for the Clinician, 1st edn, (Springer Singapore, 2021).

  147. Bakhsh, A. A., Shabeeh, H., Mannocci, F. & Niazi, S. A. A review of guidelines for antibiotic prophylaxis before invasive dental treatments. Appl. Sci. 11, 311 (2021).

    CAS  Google Scholar 

  148. Yiman, T. & Lixin, Q. Clinical considerations of organ transplant patients receiving implant therapy. Chin. J. Oral. Implantol. 29, 297–302 (2024).

    Google Scholar 

  149. Brandenburg, V. M. et al. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 77, 1566–1571 (2004).

    PubMed  Google Scholar 

  150. Hudson, D. et al. Periodontal disease and cirrhosis: current concepts and future prospects. eGastroenterology 3, e100140 (2025).

    PubMed  PubMed Central  Google Scholar 

  151. Xu, X. et al. Expert consensus on endodontic therapy for patients with systemic conditions. Int. J. Oral. Sci. 16, 45 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Kuraji, R., Shiba, T., Dong, T. S., Numabe, Y. & Kapila, Y. L. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. World J. Gastroenterol. 29, 967–996 (2023).

    CAS  PubMed  PubMed Central  Google Scholar 

  153. Somacarrera, M. L., Lucas, M., Cuervas-Mons, V. & Hernandez, G. Oral care planning and handling of immunosuppressed heart, liver, and kidney transplant patients. Spec. Care Dent. 16, 242–246 (1996).

    CAS  Google Scholar 

  154. Kamata, Y. et al. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial. Trials 21, 291 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Kamata, Y. et al. Periodontal treatment and usual care for nonalcoholic fatty liver disease: a multicenter, randomized controlled trial. Clin. Transl. Gastroenterol. 13, e00520 (2022).

    PubMed  PubMed Central  Google Scholar 

  156. Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L. & Perkovic, V. Chronic kidney disease. Lancet 398, 786–802 (2021).

    CAS  PubMed  Google Scholar 

  157. Collaborators, G. B. D. C. K. D. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 2461–2482 (2025).

    Google Scholar 

  158. He, G. et al. Chronic kidney disease burden from 1990 to 2023 in China: national and provincial insights from the Global Burden of Diseases study 2023. Lancet Reg. Health West Pac. 68, 101776 (2026).

    PubMed  Google Scholar 

  159. Shimizu, Y. et al. Association between periodontitis and chronic kidney disease by functional atherosclerosis status among older Japanese individuals: a cross-sectional study. J. Clin. Periodontol. 50, 430–439 (2023).

    PubMed  Google Scholar 

  160. Lopez-Sanz, L. et al. Chronic kidney disease and chronic oral inflammatory diseases: a systematic review and meta-analysis of periodontitis and apical periodontitis. J. Clin. Med. 14, 7947 (2025).

  161. Schmidt-Lauber, C. et al. Association of periodontitis with reduced kidney function and albuminuria in early chronic kidney disease: a population-based study. Int. J. Oral Sci. 18, 33 (2026).

  162. He, T., Li, X., Liao, C. J., Feng, X. Y. & Guo, X. Y. Association of periodontal disease with the prognosis of chronic kidney disease: a meta-analysis. J. Chin. Med. Assoc. 88, 170–177 (2025).

    CAS  PubMed  Google Scholar 

  163. Sharma, P. et al. Oxidative stress links periodontal inflammation and renal function. J. Clin. Periodontol. 48, 357–367 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  164. Ganimusa, I., Chew, E. & Lu, E. M. Vitamin D deficiency, chronic kidney disease and periodontitis. Medicina 60, 420 (2024).

  165. Santos-Paul, M. A. et al. Cardiovascular risk reduction with periodontal treatment in patients on the waiting list for renal transplantation. Clin. Transpl. 33, e13658 (2019).

    Google Scholar 

  166. Nylund, K. M. et al. Oral health in patients with renal disease: a longitudinal study from predialysis to kidney transplantation. Clin. Oral. Investig. 22, 339–347 (2018).

    PubMed  Google Scholar 

  167. Ishimaru, M. et al. Risk of surgical site infections after tooth extraction in CKD: a retrospective real-world study in Japan. Clin. J. Am. Soc. Nephrol. 20, 582–584 (2025).

    PubMed  Google Scholar 

  168. Li, S. et al. Periodontal disease and chronic kidney disease: mechanistic insights and novel therapeutic perspectives. Front. Cell Infect. Microbiol. 15, 1611097 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  169. da Silva, T. A., Abreu, L. G. & Esteves Lima, R. P. A meta-analysis on the effect of periodontal treatment on the glomerular filtration rate of chronic kidney disease individuals: a systematic review and meta-analysis was conducted to assess the impact of the periodontal treatment on the glomerular filtration rate of individuals with chronic kidney disease. Spec. Care Dent. 41, 670–678 (2021).

    Google Scholar 

  170. Almeida, S., Figueredo, C. M., Lemos, C., Bregman, R. & Fischer, R. G. Periodontal treatment in patients with chronic kidney disease: a pilot study. J. Periodontal Res. 52, 262–267 (2017).

    CAS  PubMed  Google Scholar 

  171. Wongsuwanlert, M. et al. Short-term assessment of non-surgical periodontal therapy reduces oral pathogens and pro-inflammatory cytokines, enhancing clinical outcomes in patients with chronic kidney disease. BMC Oral Health 26, 1604 (2026).

  172. Collaborators, G. B. D. C. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1565–1586 (2025).

  173. Xia, C., Li, H., Wu, C. & Chen, W. Cancer burden and control in China: landscape, trends and challenges. Nat. Rev. Clin. Oncol. 23, 694–711 (2026).

  174. Yuan J, W. S. et al. Risk of cancer in periodontal disease: an umbrella review of meta-analyses. Front. Immunol. 17, 1–13 (2026).

    Google Scholar 

  175. Nwizu, N., Wactawski-Wende, J. & Genco, R. J. Periodontal disease and cancer: epidemiologic studies and possible mechanisms. Periodontology 83, 213–233 (2020).

    Google Scholar 

  176. Higham, J. & Scannapieco, F. A. Epidemiological associations between periodontitis and cancer. Periodontology 96, 74–82 (2024).

    Google Scholar 

  177. Sasaki, M. et al. Periodontitis and postoperative inflammation in gastric cancer patients: propensity score analysis. Oral Dis. 30, 4691–4704 (2024).

    PubMed  Google Scholar 

  178. Davis, D. D., Hanley, M. E. & Cooper, J. S. Osteoradionecrosis (Archived). StatPearls Publishing (2023).

  179. Iqbal, Z. & Kyzas, P. Analysis of the critical dose of radiation therapy in the incidence of osteoradionecrosis in head and neck cancer patients: a case series. BDJ Open 6, 18 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  180. Moharrami, M. et al. Defining the optimal radiation thresholds for stratifying jaw osteoradionecrosis risk in head and neck cancer. Radiother. Oncol. 209, 110996 (2025).

    PubMed  Google Scholar 

  181. Mazzetti, T. et al. Required time for pre-oncological dental management - a rapid review of the literature. Oral. Oncol. 134, 106116 (2022).

    PubMed  Google Scholar 

  182. Watson, E. E. et al. Development and standardization of an osteoradionecrosis classification system in head and neck cancer: implementation of a risk-based model. J. Clin. Oncol. 42, 1922–1933 (2024).

    CAS  PubMed  PubMed Central  Google Scholar 

  183. Mealey, B. L., Semba, S. E. & Hallmon, W. W. The head and neck radiotherapy patient: part 2-management of oral complications. Compendium 15, 442–444 (1994).

    CAS  PubMed  Google Scholar 

  184. Xia, J. et al. Expert consensus on the prevention and treatment of radiochemotherapy-induced oral mucositis. Int J. Oral. Sci. 17, 54 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  185. Jané-Salas E, E.-Á. Y., Álvarez-García R, García Miragall E, Clemente-Tejada L, Beorlegui-Murillo P. Multidisciplinary Consensus on Oral Care in Cancer Patients https://semo.es/wp-content/uploads/2022/10/MULTIDISCIPLINARI-CONSENSUS_2.pdf (2022).

  186. Hong, C. H. et al. A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 18, 1007–1021 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  187. Pfister, D. G. et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 18, 873–898 (2020).

    Google Scholar 

  188. Han, Y. et al. The tendency of anemia of inflammation in periodontal diseases. Clin. Sci. 137, 251–264 (2023).

    CAS  Google Scholar 

  189. Huang, L. G., Yu, C. C., Lin, M. C., Wang, Y. H. & Chang, Y. C. Association between periodontitis and hematologic cancer: an NHIRD cohort study in Taiwan. Cancers 16, 1671 (2024).

  190. Gokhale, S. R., Sumanth, S. & Padhye, A. M. Evaluation of blood parameters in patients with chronic periodontitis for signs of anemia. J. Periodontol. 81, 1202–1206 (2010).

    PubMed  Google Scholar 

  191. Khan, M. A., Lal, N., Chandra, T., Ali, W. & Ismail, H. Association of ABO phenotype, rhesus factor, platelet count and hemoglobin level with oral hygiene status and severity of chronic periodontitis. J. Oral. Biol. Craniofacial Res. 14, 730–734 (2024).

    Google Scholar 

  192. Yuan, Q. et al. Ligature-induced periodontitis promotes Dnmt3a(R878H)-driven clonal hematopoiesis. Haematologica 111, 2047–2060 (2026).

    PubMed  PubMed Central  Google Scholar 

  193. Sharan, J. et al. Gingival hyperplasia: an initial oral manifestation of acute myeloid leukemia. J. Indian Soc. Periodontol. 27, 201–206 (2023).

    PubMed  PubMed Central  Google Scholar 

  194. Zadik, Y. et al. MASCC/ISOO clinical practice statement: dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy. Support Care Cancer 33, 853 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  195. Miller, C., Rhodus, N. L., Treister, N. S., Stoopler, E. T. & Kerr, A. R. Little and Falace’s Dental Management of the Medically Compromised Patient 10th edn (Elsevier Health Sciences, 2023).

  196. Oyaizu, K. et al. Periodontal treatment in severe aplastic anemia. J. Periodontol. 76, 1211–1216 (2005).

    PubMed  Google Scholar 

  197. Nickles, K., Wohlfeil, M., Alesci, S., Miesbach, W. & Eickholz, P. Comprehensive treatment of periodontitis in patients with von Willebrand disease. J. Periodontol. 81, 1432–1440 (2010).

    PubMed  Google Scholar 

  198. Lv, X. et al. Initial periodontal therapy for seven patients with aplastic anemia and drug-induced gingival overgrowth: a case series report. BMC Oral. Health 25, 847 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  199. Herrera, D. et al. Treatment of stage IV periodontitis: the EFP S3 level clinical practice guideline. J. Clin. Periodontol. 49, 4–71 (2022).

    PubMed  Google Scholar 

  200. Society of Periodontology, C. S. A. [Consensus of Chinese experts on diagnosis of severe periodontitis and treatment principles of periodontitis in special population]. Zhonghua Kou Qiang Yi Xue Za Zhi 52, 67–71 (2017).

    Google Scholar 

  201. Bertolani, Y., Garcia-Arumi, C., Goncharova, T., Arnaiz-Camacho, A. & Garcia-Arumi, J. Choroidal metastasis secondary to follicular thyroid carcinoma successfully managed with larotrectinib: a case report and review of the literature. Ann. Endocrinol. 86, 101675 (2025).

    Google Scholar 

  202. Yang, L., Zhang, S., Wang, X., Yang, J. & Chen, M. Intelligent prediction of thyroid cancer in China based on GBD data and hospital electronic medical records: disease burden analysis combined with multiple machine learning models. Front. Endocrinol. 16, 1644396 (2025).

    Google Scholar 

  203. Inchingolo, F. et al. Bidirectional association between periodontitis and thyroid disease: a scoping review. Int. J. Environ. Res. Public Health 21, 860 (2024).

  204. Puthiyapurayil, S., Vadakkekuttical, R. J., Kesavan, T. N. & Kanakkath, H. Association between periodontal parameters and thyroid markers in autoimmune hypothyroidism: a cross-sectional study. J. Periodontol. 97, 569–579 (2025).

  205. Wang, H. et al. Associations between thyroid function and periodontitis: a machine learning approach using NHANES. Int. Dent. J. 75, 100921 (2025).

    PubMed  PubMed Central  Google Scholar 

  206. Mancini, A. et al. Thyroid hormones, oxidative stress, and inflammation. Mediat. Inflamm. 2016, 6757154 (2016).

    Google Scholar 

  207. Dhanwal, D. K. Thyroid disorders and bone mineral metabolism. Indian J. Endocrinol. Metab. 15, S107–112 (2011).

    PubMed  PubMed Central  Google Scholar 

  208. Bhankhar, R. R., Hungund, S., Kambalyal, P., Singh, V. & Jain, K. Effect of nonsurgical periodontal therapy on thyroid stimulating hormone in hypothyroid patients with periodontal diseases. Indian J. Dent. Res. 28, 16–21 (2017).

    PubMed  Google Scholar 

  209. Hong, C. H., Scobey, M. W., Napenas, J. J., Brennan, M. T. & Lockhart, P. B. Dental postoperative bleeding complications in patients with suspected and documented liver disease. Oral. Dis. 18, 661–666 (2012).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Key Research and Development Program of China (No. 2023YFC2506300), National Natural Science Foundation of China (No. 82370975), National Natural Science Foundation of China (No. 82571104), Natural Science Foundation of Liaoning Province (No. 2025-MSLH-745).

Author information

Author notes

  1. These authors contributed equally: Fengxue Geng, Li Lin

Authors and Affiliations

  1. Department of Periodontics, School and Hospital of Stomatology, China Medical University, Shenyang, China

    Fengxue Geng, Li Lin, Dongmei Zhang, Chen Li & Xida Zhao

  2. Department of Periodontology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China

    Zhongchen Song

  3. Department of Periodontology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China

    Fuhua Yan

  4. Department of Periodontics, Affiliated Hospital of Stomatology, Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, China

    Yan Xu

  5. Laboratory of Tissue Regeneration and Immunology and Department of Periodontics, Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, School of Stomatology, Capital Medical University, Beijing, China

    Yi Liu

  6. Department of Periodontics and Oral Mucosa Diseases, Dalian Stomatological Hospital, Dalian, China

    Jiang Sun

  7. Department of Periodontology, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology & Research Center of Engineering, Beijing, China

    Qingxian Luan

  8. Department of Periodontology, National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology & Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health, Peking University School and Hospital of Stomatology, Beijing, China

    Wenjie Hu

  9. Department of Periodontology, School and Hospital of Stomatology, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, China

    Shaohua Ge

  10. State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi International Joint Research Center for Oral Diseases, Department of Periodontology, School of Stomatology, The Fourth Military Medical University, Xi’an, China

    Faming Chen

  11. Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, China

    Chuanjiang Zhao

  12. Department of Endocrinology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Jie Qiao

  13. Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China

    Xiaoping Chen

  14. West China Hospital, Sichuan University, Chengdu, China

    Xianghao Zuo

  15. Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China

    Xinghui Liu

  16. Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University; Beijing Institute of Respiratory Medicine, Beijing Key Laboratory of Multimodal Intelligent Diagnosis and Treatment System for Respiratory Diseases, Beijing, China

    Li An

  17. Department of Stomatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

    Zuomin Wang

  18. State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Periodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China

    Yi Ding

  19. Department of Periodontics and Oral Biology, Liaoning Provincial Key Laboratory of Oral Diseases, School and Hospital of Stomatology, China Medical University, Shenyang, China

    Yaping Pan

Authors

  1. Fengxue Geng
  2. Li Lin
  3. Zhongchen Song
  4. Fuhua Yan
  5. Yan Xu
  6. Yi Liu
  7. Jiang Sun
  8. Qingxian Luan
  9. Wenjie Hu
  10. Shaohua Ge
  11. Faming Chen
  12. Chuanjiang Zhao
  13. Jie Qiao
  14. Xiaoping Chen
  15. Xianghao Zuo
  16. Xinghui Liu
  17. Li An
  18. Zuomin Wang
  19. Dongmei Zhang
  20. Chen Li
  21. Xida Zhao
  22. Yi Ding
  23. Yaping Pan

Contributions

Conceptualization and Investigation, Y.P. Pan and Y. Ding; Supervision, Y.P. Pan and Y. Ding; Original draft, F.X. Geng and L. Lin; Review and editing, F.X. Geng, L. Lin, Z.C. Song, F.H. Yan, Y. Xu, Y. Liu, J. Sun, Q.X. Luan, W.J. Hu, S.H. Ge, F.M. Chen, C.J. Zhao, J. Qiao, X.P. Chen, X.H. Zuo, X.H. Liu, L. An, Z.M. Wang, D.M. Zhang, C. Li, X.D. Zhao, Y. Ding, and Y.P. Pan.

Corresponding authors

Correspondence to Yi Ding or Yaping Pan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Geng, F., Lin, L., Song, Z. et al. Expert consensus on periodontal management for medically compromised patients. Int J Oral Sci 18, 74 (2026). https://doi.org/10.1038/s41368-026-00471-2

Download citation

  • Received: 31 March 2026

  • Accepted: 21 September 2026

  • Published: 20 November 2026

  • Version of record: 20 November 2026

  • DOI: https://doi.org/10.1038/s41368-026-00471-2

来源:Nature 健康护理主题 · nature.com